Skip to main content
placeholder image

Galectin-1 as a potent target for cancer therapy: Role in the tumor microenvironment

Journal Article


Abstract


  • The microenvironment of a tumor is a highly complex milieu, primarily characterized by immunosuppression, abnormal angiogenesis, and hypoxic regions. These features promote tumor progression and metastasis, resulting in poor prognosis and greater resistance to existing cancer therapies. Galectin-1 is a β-galactoside binding protein that is abundantly secreted by almost all types of malignant tumor cells. The expression of galectin-1 is regulated by hypoxia-inducible factor-1 (HIF-1) and it plays vital pro-tumorigenic roles within the tumor microenvironment. In particular, galectin-1 suppresses T cell-mediated cytotoxic immune responses and promotes tumor angiogenesis. However, since galectin-1 displays many different activities by binding to a number of diverse N- or O-glycan modified target proteins, it has been difficult to fully understand how galectin-1 supports tumor growth and metastasis. This review explores the importance of galectin-1 and glycan expression patterns in the tumor microenvironment and the potential effects of inhibiting galectin-1 as a therapeutic target for cancer treatment. © 2012 Springer Science+Business Media, LLC.

Publication Date


  • 2012

Citation


  • Ito, K., Stannard, K., Gabutero, E., Clark, A. M., Neo, S. Y., Onturk, S., . . . Ralph, S. J. (2012). Galectin-1 as a potent target for cancer therapy: Role in the tumor microenvironment. Cancer and Metastasis Reviews, 31(3-4), 763-778. doi:10.1007/s10555-012-9388-2

Scopus Eid


  • 2-s2.0-84867990611

Start Page


  • 763

End Page


  • 778

Volume


  • 31

Issue


  • 3-4

Abstract


  • The microenvironment of a tumor is a highly complex milieu, primarily characterized by immunosuppression, abnormal angiogenesis, and hypoxic regions. These features promote tumor progression and metastasis, resulting in poor prognosis and greater resistance to existing cancer therapies. Galectin-1 is a β-galactoside binding protein that is abundantly secreted by almost all types of malignant tumor cells. The expression of galectin-1 is regulated by hypoxia-inducible factor-1 (HIF-1) and it plays vital pro-tumorigenic roles within the tumor microenvironment. In particular, galectin-1 suppresses T cell-mediated cytotoxic immune responses and promotes tumor angiogenesis. However, since galectin-1 displays many different activities by binding to a number of diverse N- or O-glycan modified target proteins, it has been difficult to fully understand how galectin-1 supports tumor growth and metastasis. This review explores the importance of galectin-1 and glycan expression patterns in the tumor microenvironment and the potential effects of inhibiting galectin-1 as a therapeutic target for cancer treatment. © 2012 Springer Science+Business Media, LLC.

Publication Date


  • 2012

Citation


  • Ito, K., Stannard, K., Gabutero, E., Clark, A. M., Neo, S. Y., Onturk, S., . . . Ralph, S. J. (2012). Galectin-1 as a potent target for cancer therapy: Role in the tumor microenvironment. Cancer and Metastasis Reviews, 31(3-4), 763-778. doi:10.1007/s10555-012-9388-2

Scopus Eid


  • 2-s2.0-84867990611

Start Page


  • 763

End Page


  • 778

Volume


  • 31

Issue


  • 3-4